Alzheimer's disease drug development in 2008 and beyond: problems and opportunities.

Alzheimer's disease drug development in 2008 and beyond: problems and opportunities. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Alzheimer's disease drug development in 2008 and beyond: problems and opportunities. Abstract Text:

Alzheimer's disease drug development in 2008 and beyond: problems and opportunities. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Alzheimer's disease drug development in 2008 and beyond: problems and opportunities. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Current Alzheimer research

VOLUME: 5

Page Numbers: 346-57

Journal Abbreviation:

ISSN: 1567-2050

DAY: 11

MONTH: Aug

YEAR: 2008

Alzheimer's disease drug development in 2008 and beyond: problems and opportunities. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 101208441

Alzheimer's disease drug development in 2008 and beyond: problems and opportunities. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Alzheimer's disease drug development in 2008 and beyond: problems and opportunities. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Alzheimer's disease drug development in 2008 and beyond: problems and opportunities.

AFFILIATION: Drug Design & Development Section, Laboratory of Neurosciences, Intramural Research Program, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA. rebecker2008@comcast.net.

Country: United Arab Emirates

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Curr Alzheimer Res

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Alzheimer's disease drug development in 2008 and beyond: problems and opportunities Related Publications

• Allergic contact dermatitis to all three classes of local anaesthetic.
• Alzheimer's disease drug development in 2008 and beyond: problems and opportunities.
• An analysis of resection vs transplantation for early hepatocellular carcinoma: defining the optimal therapy at a single institution.
• Apoptotic and behavioral sequelae of mild brain trauma in mice.
• Bullous systemic lupus erythematosus responding to dapsone.
• Christman-factor (factor IX) deficiency produced by concurrent administration of heparin with coumarin drugs.
• DIBENZO(B,E)(1,4)DIAZEPINES.
• Dietary fat and coronary disease.
• Differential effects of two hexahydropyrroloindole carbamate-based anticholinesterase drugs on the amyloid beta protein pathway involved in Alzheimer's disease.
• Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy.
• Inhibition of fibrinolysis by alimentary lipaemia.
• Kinetics of human serum butyrylcholinesterase inhibition by a novel experimental Alzheimer therapeutic, dihydrobenzodioxepine cymserine.
• LOUIS GREIG.
• Letter: Effect of natural oestrogens on coagulation.
• Modern architecture.
• Neurine, an acetylcholine autolysis product, elevates secreted amyloid-beta protein precursor and amyloid-beta peptide levels, and lowers neuronal cell viability in culture: a role in Alzheimer's disease?
• Post-operative thrombosis; investigation of a proposed test for its prediction.
• Practical points.
• Prezygotic reproductive isolation between Saccharomyces cerevisiae and Saccharomyces paradoxus.
• Recurrent pyogenic cholangitis with hepatolithiasis-the role of surgical therapy in north america.
• Results of surgery for ingrowing toenails.
• Soccer half-time strategy influences thermoregulation and endurance performance.
• TNF-alpha inhibition as a treatment strategy for neurodegenerative disorders: new drug candidates and targets.
• Tetrahydrofurobenzofuran cymserine, a potent butyrylcholinesterase inhibitor and experimental Alzheimer drug candidate, enzyme kinetic analysis.
• The experimental Alzheimer's disease drug posiphen [(+)-phenserine] lowers amyloid-beta peptide levels in cell culture and mice.
• The influence of soccer-specific fatigue on peak isokinetic torque production of the knee flexors and extensors.
• The inhibition of hexokinase by amidone (2-dimethylamino-4,4-diphenylheptanone-5-hydrochloride).
• Water-jet dissection for parenchymal division during hepatectomy.